Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study - Takeaways - MDSpire

Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study

  • By

  • Soroush Masrouri

  • Parag A Chevli

  • Michael P Bancks

  • Saeid Mirzai

  • João A C Lima

  • David A Bluemke

  • Neha J Pagidipati

  • Michael D Shapiro

  • November 3, 2025

  • 0 min

Share

  • 1

    The study analyzed urine albumin-creatinine ratio (UACR) trajectories over 5- and 10-year periods in relation to heart failure and cardiovascular diseases.

  • 2

    Three distinct UACR trajectory groups were identified: 'slow rise at low level', 'slow rise at medium level', and 'sustained medium to high' or 'rapid rise'.

  • 3

    Participants in the 'sustained medium to high' and 'rapid rise' UACR groups had significantly increased risks of heart failure, atrial fibrillation, and coronary heart disease.

  • 4

    Associations between UACR trajectories and heart failure remained significant even among individuals with normoalbuminuria at baseline.

  • 5

    The findings suggest that progressive increases in UACR are early markers of cardiovascular risk, particularly for heart failure.

Original Source(s)

Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study

  • by Soroush Masrouri, Parag A Chevli, Michael P Bancks, Saeid Mirzai, João A C Lima, David A Bluemke, Neha J Pagidipati, Michael D Shapiro

  • November 3, 2025

Related Content

Outcomes following coronary artery bypass grafting with temporary left ventricular assist device support

Role of psychological resilience and psychological distress in linking fear of disease progression to quality of life in chronic heart failure: a cross-sectional serial mediation analysis

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.